Pilot Study of Lapatinib (Tyverb®) in Neoadjuvant Treatment for Patients With Locally Bladder Carcinoma Before Cystectomy
试验速览
- 阶段
- 早期 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Effect on egf pathway at a molecular level of 3 weeks treatment by lapatinib.
研究概览
简要总结
Modification of the EGF signalling pathway and / or HER 2, by Lapatinib in bladder cancer.
详细描述
Patients with invasive bladder tumor , candidates for radical cystectomy. Patients will receive Lapatinib during 3 weeks +/- 5 days, before cystectomy. A comparison of tissue from the original biopsy and cystectomy after Lapatinib will allow this to occur.
TREATMENT AND STRATEGY Lapatinib in bladder carcinoma -Overall there are arguments for considering that egf pathway is involved in bladder carcinoma and so far that drugs inhibiting EGF pathway could have an impact for therapeutical endpoints.
Nevertheless it is unclear that from previous studies that adding egf inhibiting drug to chemotherapy is clinically relevant, essentially by difficulties to measure a beneficial endpoint while downstream EGF pathways have been modified by these drugs, as shown with lapatinib (see 2.1.5).
Furthermore, there is no argument for initial selection of patients based on the initial egfr and/or her 2 tumor profile, asking for more intense knowledge.
LAPATINIB TREATMENT Patients will receive lapatinib therapy at a daily standard dose of 1500 mg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must sign and date IRB/EC-approved informed consent,
- •Patients must have a life expectancy of at least 6 months,
- •Patients must have a Karnofsky performance status ≥ 80%,
- •Clinical stage T2NxM0 to T4aNxM0 bladder cancer
- •Muscle-invasive transitional cell carcinoma by histology (focal squamous and/or adenocarcinoma differentiation defined as ≤ 10% of tumor volume allowed, sarcomatoid and small-cell components not allowed)
- •Considered to have a macroscopic residue in the bladder to allow comparison of tissue samples at cystectomy to initial biopsies
- •Candidates for radical cystectomy
- •Patient with normal cardiac function, LVEF ≥ 50% measured by echocardiography or MUGA scan
- •Able to swallow and retain oral medication
- •A female is eligible to enter and participate in this study if she is of : Non-child-bearing potential (i.e., a woman with functioning ovaries who have a current documented tubal ligation or hysterectomy or a woman who is menopausal), or Child-bearing potential (i.e. a woman with functioning ovaries and no documented impairment of oviductal or uterine function that would cause sterility. This category includes women with oligomenorrhoea (even severe), women who are perimenopausal and young women who have begun to menstruate), who have a negative serum pregnancy test at screening, and agree to one of the following consistent and correct use of one acceptable methods of birth control : Any intrauterine device (IUD) with a documented failure rate of less than 1% per year, or combined oral contraception
- •care must be taken to avoid pregnancy in partners of male patients.
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- •Affiliated or profit patient of a social security system
排除标准
- •Prior pelvic radiation or neoadjuvant chemotherapy.
- •Pregnancy or breastfeeding.
- •Other severe acute or chronic medical or psychiatric condition that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •Patients with significantly reduced LVEF or LVEF < 50%.
- •Patient with any of the following liver abnormal laboratory test :
- •Serum bilirubin > 1,5 x upper limit of normal (ULN) (in case of Gilbert syndrome, a higher serum total bilirubin (< 2 ULN) is allowed
- •Alanine amino transferase (ALAT) or aspartate amino transferase (ASAT) > 2,5 ULN
- •Platelets <100 x 109/L, hemoglobin < 9 g/dl, absolute neutrophil count (ANC) <1.5 x 109/L
- •Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- •Serum creatinine > 1.5 x ULN.
- •Previous therapy targeting EGFR or HER-
- •Predominantly non transitional cell histology.
- •Diagnosis of any second malignancy within the last 3 years, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix uteri that has been adequately treated with no evidence of recurrent disease for 12 months.
- •Malabsorption syndrome, disease significantly affecting gastrointestinal function, or major resection of the stomach or bowel, that could affect absorption of lapatinib.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
- •Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, that would limit compliance with study requirements.
- •History of uncontrolled or symptomatic angina
- •History of arrhythmias requiring medications, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation
- •Myocardial infarction < 6 months from study entry
- •Uncontrolled or symptomatic congestive heart failure
- •Ejection fraction below the institutional normal limit
- •Any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
- •Use of an investigational agent within 30 days or 5 half-lives, whichever is the longer, preceding the first dose of investigational product.
- •Concurrent treatment with an investigational agent
- •Concurrent treatment with cytotoxic chemotherapy, immunotherapy, biologic therapy, hormonal therapy or curative radiotherapy for locally advanced or metastatic TCC of the urothelial tract.
- •Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors.
- •Patient under safeguard of justice
研究组 & 干预措施
Patient
干预措施: LAPATINIB (Drug)
结局指标
主要结局
Effect on egf pathway at a molecular level of 3 weeks treatment by lapatinib.
时间窗: At surgery (day 21-27)
The primary objective of the study is to evaluate the effect at a molecular level, of 3 weeks of neoadjuvant lapatinib, in locally advanced muscle-invasive transitional cell carcinoma of the bladder. A comparison of tissue from the original biopsy and cystectomy after lapatinib will allow this to occur. This effect will be evaluated by studying proliferation and apoptotic markers as well as the phosphorylation of proteins which are components of the egf signalling pathway.
次要结局
- Lapatinib biological response on key molecules of the egf pathway (EGFR, ERBB2, AKT ERK as well as their phosphorylation status.)(At screening (day -10 before inclusion) , surgery (day 21-27) and Follow up visit surgery (day 42-62))
- Histological response(At surgery (day 21-27))